33334-08-6

Usage

Uses

Used in Pharmaceutical Research:
N-Amino-1H-indazole is used as a research compound for its potential medicinal applications, given its indazole/pharmacore moiety. It is employed in various research settings to explore its properties and possible therapeutic uses.
Used in Chemical Synthesis:
N-Amino-1H-indazole is used as a synthetic intermediate in the preparation of other chemical compounds, particularly in the pharmaceutical and chemical industries, due to its reactivity and potential for forming new molecules with desired properties.
Used in Material Science:
N-Amino-1H-indazole is used as a component in the development of new materials, such as in the creation of organic electronic devices, where its electronic properties and solubility in organic solvents are advantageous.
Used in Toxicological Studies:
N-Amino-1H-indazole is used as a test compound in toxicological studies to understand its effects on biological systems, which can help in assessing its safety profile and potential risks associated with its use in various applications.

InChI:InChI=1/C7H7N3/c8-10-7-4-2-1-3-6(7)5-9-10/h1-5H,8H2

Upstream product

• 271-44-3 benzimidazole 
• 71-36-3 butan-1-ol 

Downstream Products

• 111042-00-3 Indazol-1-yl-[1-(5-nitro-furan-2-yl)-meth-(E)-ylidene]-amine 
• 271-44-3 benzimidazole 
• 97990-19-7 3-Amino-2-methyl-2H-indazol 
• 243-51-6 11H-indeno[1,2-b]quinoline 
• 1531-62-0 2-butyl-3-methylquinoline 
• 5661-06-3 2,3-dihydro-1H-cyclopenta[b]quinoline 
• 1666-96-2 3-phenylquinoline 
• 3295-64-5 1,2,3,4-tetrahydroacridine 
• 1613-32-7 2-n-Propylquinoline 
• 1613-34-9 2-ethylquinoline 
• 253-83-8 1,2,3-benzotriazine 

Relevant academic research and scientific papers

1-[(imidazolidin-2-yl)imino]indazole. Highly α2/I 1 selective agonist: Synthesis, X-ray structure, and biological activity

Novel benzazole derivatives bearing a (imidazolidin-2-yl)imino moiety at position 1 or 2 were synthesized by reacting 1-amino- or 2-aminobenzazoles with N,N′-bis(tert-butoxycarbonyl)imidazolidine-2-thione in the presence of HgCl2. Structures of

Method and compositions for identifying anti-HIV therapeutic compounds

Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors

The present invention relates to compounds of formulae I and II: STR1 or pharmaceutically acceptable salt forms or prodrugs thereof, which are useful as inhibitors of HIV protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Synthesis and structure-activity relationships of N-propyl-N-(4- pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease

A series of novel N-(4-pyridinyl)-1H-indol-1-amines and other heteroaryl analogs was synthesized and evaluated in tests to determine potential utility for the treatment of Alzheimer's disease. From these compounds, N-propyl-N- (4-pyridinyl)-1H-indol-1-amine (besipirdine, 4c) was selected for clinical development based on in-depth biological evaluation. In addition to cholinomimetic properties based initially on in vitro inhibition of [3H]quinuclidinyl benzilate binding, in vivo reversal of scopolamine- induced behavioral deficits, and subsequently on other results, 4c also displayed enhancement of adrenergic mechanisms as evidenced in vitro by inhibition of [3H]clonidine binding and synaptosomal biogenic amine uptake, and in vivo by reversal of tetrabenazine-induced ptosis. The synthesis, structure-activity relationships for this series, and the biological profile of 4c are reported.

3-substituted cephem compounds

The present invention relates to novel cephalosporins of the formula (I); STR1 wherein, R1 represents a C1 ?C4 alkyl group or STR2 wherein, R2 and R3, independently, represent hydrogen or a C1 ?C3 alkyl group and R4 represents hydrogen or a C1 ?C4 alkyl group; R1a represents hydrogen or an amino-protecting group; Q represents CH or N; and the formula STR3 represents a saturated or unsaturated heterocyclic group which contains 1 to 4 nitrogen atoms of which one is substituted with an amino group to form quaternary ammonium, and oxygen or sulfur, or a fused heterocyclic group thereof formed together with a substituted or unsubstituted benzene or an optional heterocyclic group, or a pharmaceutically acceptable salt thereof, to processes for preparing the same and to a pharmaceutical composition containing the same as an active ingredient. The compounds(1) according to the invention exhibit potent antibacterial activity and broad antibacterial spectrum against the Gram-positive strains including Staphylococcus as well as Gram-negative strains including Pseudomonas, and, therefore, are expected to be very useful in treatment of various diseases caused by bacterial infection in human beings and animals.